Assessment of the Safety and Efficacy of Tenofovir- Lamivudine-Dolutegravir Combination Therapy a mong HIV-infected Patients in University of Uyo Teaching Hospital, Uyo, Nigeria

Authors

  • Olugbenga M. Ajulo Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Uyo, Uyo. Akwa-Ibom State. Nigeria.
  • Rita E. Udoh Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Uyo, Uyo. Akwa-Ibom State. Nigeria.
  • Emmanuel O. Olorunsola Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Uyo, Uyo. Akwa-Ibom State. Nigeria.
  • Oluwatoyin H. Ajulo Department of Animal Science, Faculty of Agriculture, University of Uyo, Uyo. Akwa-Ibom State. Nigeria.

DOI:

https://doi.org/10.51412/psnnjp.2024.26

Keywords:

AIDS, Antiretroviral, Drug toxicity, Hepatotoxicity, HIV, Renotoxicity
         Abtract Views | PDF Download: 36 / 4

Abstract

Background: Clinical outcomes are measurable changes in health, function or quality of life that result from professional care. Examples of clinical outcomes are cure, clinical worsening and death. Due to life-threatening toxicity of Zidovudine, Lamivudine and Nevirapine combination and Tenofovir, Lamivudine and Efavirenz antiretroviral combination in Nigeria, a new therapy, Tenofovir,
Lamivudine and Dolutegravir (TLD) combination had become first-line drug regimen. Study aimed at assessing the safety and efficacy of TLD combination therapy.

Method: This was a longitudinal, multi-phase non-interventional study involving 194 asymptomatic HIV-infected patients attending antiretroviral clinic in University of Uyo Teaching Hospital. Data were collected through a purposive convenience sampling technique after obtaining ethical approval and informed consent were filled. Questionnaires were administered to the study participants for
demographic and medication information and clinical parameters such as viral load and CD4-count were collated from their case files. A 5mL venous blood sample was collected from participants for liver and kidney function tests at baseline (0 month), 3 months- and 6 months-post baseline respectively. Blood samples of study participants were stored in the freezer after separation and were
analyzed at the end of every week in the hospital laboratory. Alanine aminotransferase (ALT), Alkaline phosphatase (ALP) and Aspartate aminotransferase (AST) were biomarkers evaluated for liver functions while serum creatinine was evaluated for kidney function. The blood samples were properly disposed by the hospital laboratory scientist. Biochemical assays of liver enzymes ALT and AST and
creatinine test were carried out by using Randox® reagents. The results obtained were analyzed using SPSS version 25. ANOVA was used to compare data of biochemical parameters across the three phases of study while p ≤ 0.05 was considered significant.

Results: The results showed that 55 participants completed the three phases with CD4-counts 482.90±251.72, 486.67±172.28 and  17.0±180.60cells/mm3 at 0-, 3- and 6-month respectively. The Liver enzyme ALT was normal in all Phases while AST mean-values were elevated in all Phases. ALT, AST and AST/ALT ratio were significantly varied from the baseline at 3-month (0.001, 0.000 and 0.000) and 6-month (0.093, 0.000 and 0.000) respectively. The creatinine clearance was below normal limit and continued to fall with time for both males (67.79±20.96-, 65.26±18.76- and 64.70±19.62mL/min) and females (75.8±20.66-, 70.07±20.66- and 69.60±21.90mL/min)
respectively.

Conclusion: This study indicated that there was significantly decreased viral load of study participants while CD4 count was increased. The study also indicated that biochemical parameters of liver function, enzymes ALT and ALP were significantly increased in participants. The study also indicated that creatinine clearance of participants was significantly reduced in post-baseline follow-up. The
most common complaint by participants on TLD was insomnia. Six study participants on TLD were confirmed dead. 

References

World Health Organization. HIV – Number of people dying from HIV-related causes (who.int). 2 0 2 2 . https://www.who.int/data/gho/data/ndicators / indicator-details/gho/number-of-deaths-due-to-hiv-aids

Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resourcelimited settings. Lance t2006; 368: 505-10.

Updated recommendations on first-line and second-line antiretroviral regimens and post- exposure prophylaxis and recommendations on early infant diagnosis of HIV. Geneva: World Health Organization, January 1, 2018 (https://www.who.int/publications/i/item/WHO- CDS-HIV-18.51).

Update of recommendations on first and second- line antiretroviral regimens. Geneva: World Health Organization, July 2019 (https://apps.who.int/iris/bitstream/handle/10665 /325892/WHO-CDS-HIV-19.15-eng.pdf?ua= 1).

UNAIDS. (2019) Closing the HIV resource gap in Nigeria with more domestic funding” .

UNAIDS. AIDS info (2020) Schauer G, Leuba S, Sluis-Cremer N (2013) Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Biomolecules 2013,3:889-904.

Indikit. Sample Size Formula 2021. www.indikit.net Ajulo MO, Omole MK, Moody JO (2014) Impact of highly active antiretroviral therapy (HAART) on organs of HIV-infected children in Abia State, Nigeria. British Journal of Pharmaceutical Research 4(7): 837-848. .

Cock-croft D, Gault M (1976) Predictions of creatinine clearance from serum creatinine. Nephron 16 (1): 31-41.

Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S (2015) Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovirdisoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy- naive adults over 144 weeks. AIDS 29:2459–2464.Hill

AM, Mitchell N, Hughes S, Pozniak AL (2018) Risks of cardiovascular or central nervoussystem adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta- analysis of randomized trials. Current Opinion in HIV AIDS (2):102-111.

Daniel C, Burakoff S (2020) Overview of ALT and AST Liver Enzymes Very well health dot dash Inc. Saivenkat H, Vagvala L, O'Connor S (2018) Clinical Liver Disease (Hoboken) Imaging of abnormal liver function tests American Association for the Study of Liver Diseases 11(5):128-134. doi: 10.1002/cld.704.

Cristelli MP, Trullàs JC, Cofán F, Rico N, Manzardo C, Ambrosioni J, Bedini JL, Moreno A, Diekmann F, Miro JM; CKD-H. Clinical Investigators.(2018) Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. Brazilian Journal of Infectious Diseases 22(3):193-201. doi: 10.1016/j.bjid.2018.05.001.

Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD (2008). Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. Journal of Infectious Disease 197(11):1548–1557. doi: 10.1086/587994.

Carter M (2020) Weight gain & lipodystrophy, Genetics may contribute to weight gain after switching from efavirenz to an integrase inhibitor. AIDSMAP.com/archive/Micheal Carter.

Manne-Goehler J,Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, Brennan AT, Sledner MJ, Hill A, Venter WDF (2024) Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. Journal of the International AIDS Society 27(7) e26268. https://doi.org/10.1002/jia2.26268.

McCann K. (2019) The ADVANCE clinical trial: changes from baseline to week 96 in DXA- assessed body composition in TAF/FTC +DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV. 17th European AIDS Conference, Basel, abstract PS3/3.

Venter W, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N (2020) Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The Lancet HIV 7: e666-e676.

Mugglin C, Calmy A, Gunthard H, Tarr P, Atkinson A, Scherrer A (2019) Changes in weight after switching to dolutegravir containing

antiretroviral therapy in the Swiss HIV cohort study. European AIDS Conference (EACS) Basel, Switzerland, 6-9

Quercia R., Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco MB (2016) Psychiatric Symptoms in Patients Receiving Dolutegravir AIDS Journal of Acquired Immune Deficiency Syndromes 74(4) DOI:10.1097/QAI.0000000000001269

Michael C (2016) Doctors in Netherlands observe higher than expected dolutegravir treatment discontinuation rate. Aidsmap.com

Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C (2017) Higher Rates of Neuropsychiatric Adverse Events Leading to Dolutegravir Discontinuation in Women and Older Patients. HIV Medicine 18(1):56-63.

Hou J, Nast CC (2018) Changing concept of HIV infection and renal disease. Journal of Current opinion in Nephroogy and Hypentension (3):144-152

Verboeket S, Boyd A, Wit FW, Verheij E, Van-der S, Loeff M, Kootstra N (2019) Switching to an integrase inhibitor containing antiretroviral regimen is not associated with above-average weight gain in middle-aged people living with HIV on long-term suppressive antiretroviral therapy, the AGEhIV Cohort Study. European AIDS Conference (EACS) Basel, Switzerland.

Koethe J, Jenkins C, Lau B, Shepherd B, Justice A, Tate J, Buchacz K, Napravnik S, Mayor A, Horberg M, Blashill A, Willig A, Wester C, Silverberg M, Gill J, Thorne J, Klein M, Eron M, Kitahata M, Sterling T, Moore D (2016) Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) 2-16. PMID: 26352511 PMCID: PMC4692122 DOI: 10.1089/aid.2015.0147

Sax P, Erlandson K, Lake J, Mccomsey G, Orkin C, Esser S, Brown T, Rockstroh J, Wei X, Carter C (2019) Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials Clinical Infectious Diseases Journal 71 (6) 15: 1379–1389, https://doi.org/10.1093/cid/ciz999

Nhean, S, Yoong D, Wong DK, Gough K, Tseng AL (2019). Probable hepatotoxicity with dolutegravir: report of two cases and review of the literature. AIDS 33(7):1261-1263. doi: 10.1097/QAD.0000000000002191

Kumar S, Samaras K (2018) The Impact of Weight Gain During HIV Treatment on Risk of Pre- diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinology (Lausanne). 9: 705. doi: 10.3389/fendo.2018.00705.doi:10.3389/fendo.2018.00705. eCollection.

Downloads

Published

2024-11-04

How to Cite

Ajulo, O. M., Udoh, R. E., Olorunsola, E. O., & Ajulo, O. H. (2024). Assessment of the Safety and Efficacy of Tenofovir- Lamivudine-Dolutegravir Combination Therapy a mong HIV-infected Patients in University of Uyo Teaching Hospital, Uyo, Nigeria. The Nigerian Journal of Pharmacy, 58(2), 278–288. https://doi.org/10.51412/psnnjp.2024.26